Whatever REDUCE-IT ultimately reveals (results from the completed study are expected in Q2 or Q3 2018), Salyer maintains Amarin has “a great story to tell, with or without the data.”
Five things for pharma marketers to know: Wednesday, December 6, 2017
FDA approves Novo’s diabetes drug; Walgreens undergoes rebranding in the wake of CVS-Aetna merger; pharma increasingly transparent about clinical trial data
6 Corporate Pharma Sites that Offer Strong User Experiences
FDA approves first digital pill; biotech companies race to develop cancer-fighting microbiome drugs; Loxo and Bayer reach $1.55 billion deal for rare cancer drugs